---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010439"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:37:56.590496+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics board member Brad Bolzon resigns after nearly a decade

## Summary
- Brad Bolzon, Chairman and Managing Director of Versant Ventures, resigned from CRISPR Therapeutics board effective March 28, 2023.
- Resignation was not due to any dispute or disagreement with the company or its board.
- Bolzon served nearly a decade and was instrumental in defining the company's vision and strategy since its founding.
- No replacement named; company expressed gratitude for his contributions.

## SEC filing metadata
- accession: 0000950170-23-010439
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023010439/0000950170-23-010439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023010439/crsp-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010439
- JSON: https://secwatch.observer/filing/0000950170-23-010439.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010439.txt

## Key facts
- Executive change
  Bradley Bolzon resigned as director at CRISPR Therapeutics AG.
  - Action: resigned
  - Role: director
  source text: On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the “Company”) of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023010439/0000950170-23-010439-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.